Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Phathom Pharmaceuticals (PHAT) Share-based Compensation (2022 - 2025)

Historic Share-based Compensation for Phathom Pharmaceuticals (PHAT) over the last 4 years, with Q3 2025 value amounting to $9.3 million.

  • Phathom Pharmaceuticals' Share-based Compensation rose 6498.67% to $9.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $29.8 million, marking a year-over-year decrease of 2896.24%. This contributed to the annual value of $24.0 million for FY2024, which is 4659.19% down from last year.
  • Per Phathom Pharmaceuticals' latest filing, its Share-based Compensation stood at $9.3 million for Q3 2025, which was up 6498.67% from $8.3 million recorded in Q2 2025.
  • In the past 5 years, Phathom Pharmaceuticals' Share-based Compensation ranged from a high of $24.6 million in Q4 2023 and a low of $5.5 million during Q1 2025
  • For the 4-year period, Phathom Pharmaceuticals' Share-based Compensation averaged around $7.8 million, with its median value being $6.1 million (2023).
  • In the last 5 years, Phathom Pharmaceuticals' Share-based Compensation soared by 26929.55% in 2023 and then tumbled by 7279.94% in 2024.
  • Phathom Pharmaceuticals' Share-based Compensation (Quarter) stood at $6.7 million in 2022, then soared by 269.3% to $24.6 million in 2023, then plummeted by 72.8% to $6.7 million in 2024, then soared by 39.03% to $9.3 million in 2025.
  • Its Share-based Compensation was $9.3 million in Q3 2025, compared to $8.3 million in Q2 2025 and $5.5 million in Q1 2025.